Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  CAS  Google Scholar 

Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev. 2015;95(3):727–48. https://doi.org/10.1152/physrev.00030.2014.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Peeters PJ, Bazelier MT, Leufkens HG, et al. Insulin glargine use and breast cancer risk: Associations with cumulative exposure. Acta Oncol. 2016;55(7):851–8. https://doi.org/10.3109/0284186x.2016.1155736.

Article  PubMed  CAS  Google Scholar 

Suissa S, Azoulay L, Dell’Aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia. 2011;54(9):2254–62. https://doi.org/10.1007/s00125-011-2190-9.

Article  PubMed  CAS  Google Scholar 

Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 2010;21(10):610–8. https://doi.org/10.1016/j.tem.2010.06.007.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chiefari E, Mirabelli M, La Vignera S, et al. Insulin Resistance and Cancer: In Search for a Causal Link. Int J Mol Sci. 2021;22(20):11137.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tang X, Yang L, He Z, Liu J. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis. PLoS ONE. 2012;7(12):e51814. https://doi.org/10.1371/journal.pone.0051814.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Du X, Zhang R, Xue Y, et al. Insulin glargine and risk of cancer: a meta-analysis. Int J Biol Markers. 2012;27(3):e241-246. https://doi.org/10.5301/jbm.2012.9349.

Article  PubMed  CAS  Google Scholar 

Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012;38(6):485–506. https://doi.org/10.1016/j.diabet.2012.08.011.

Article  PubMed  CAS  Google Scholar 

Chen YB, Chen Q, Wang Z, Zhou J. Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS ONE. 2013;8(11):e81594. https://doi.org/10.1371/journal.pone.0081594.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Karlstad O, Starup-Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8(5):333–48. https://doi.org/10.2174/15680266113136660067.

Article  PubMed  CAS  Google Scholar 

Bronsveld HK, ter Braak B, Karlstad Ø, et al. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res. 2015;17(1):100. https://doi.org/10.1186/s13058-015-0611-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu JW, Filion KB, Azoulay L, Doll MK, Suissa S. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. Diabetes Care. 2016;39(3):486–94. https://doi.org/10.2337/dc15-1816.

Article  PubMed  CAS  Google Scholar 

Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes Control. 2016;27(5):709–20. https://doi.org/10.1007/s10552-016-0744-3.

Article  PubMed  PubMed Central  Google Scholar 

Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project. Cancer Causes Control. 2012;23(7):1193–203. https://doi.org/10.1007/s10552-012-9989-7.

Article  PubMed  PubMed Central  Google Scholar 

Bradley MC, Chillarige Y, Lee H, et al. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins. Diabetes Care. 2020;43(4):785–92. https://doi.org/10.2337/dc19-0614.

Article  PubMed  CAS  Google Scholar 

Grimaldi-Bensouda L, Cameron D, Marty M, et al. Risk of breast cancer by individual insulin use: an international multicenter study. Diabetes Care. 2014;37(1):134–43. https://doi.org/10.2337/dc13-0695.

Article  PubMed  Google Scholar 

Calip GS, Yu O, Hoskins KF, Boudreau DM. Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control. 2015;26(8):1065–77. https://doi.org/10.1007/s10552-015-0599-z.

Article  PubMed  PubMed Central  Google Scholar 

Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33(6):1304–8. https://doi.org/10.2337/dc09-1791.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol. 2011;123(2):200–4. https://doi.org/10.1016/j.ygyno.2011.06.038.

Article  PubMed  CAS  Google Scholar 

Redaniel MTM, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control. 2012;23(11):1785–95. https://doi.org/10.1007/s10552-012-0057-0.

Article  PubMed  Google Scholar 

Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011;34(9):1965–71. https://doi.org/10.2337/dc11-0699.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aydin Y, Erden M, Ermis F, et al. Oral antidiabetics and insulins do not increase cancer risk. Acta Medica Mediterranea. 2013;29(4):859–67.

Google Scholar 

Stürmer T, Marquis MA, Zhou H, et al. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care. 2013;36(11):3517–25. https://doi.org/10.2337/dc13-0263.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin Glargine among adult type 2 diabetes patients - a nationwide Cohort study. PLoS ONE. 2011;6(6):e21362. https://doi.org/10.1371/journal.pone.0021368.

Article  CAS  Google Scholar 

Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55(1):51–62. https://doi.org/10.1007/s00125-011-2312-4.

Article  PubMed  CAS  Google Scholar 

Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012;55(3):644–53. https://doi.org/10.1007/s00125-011-2429-5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tseng CH. Treatment with human insulin does not increase thyroid cancer risk in patients with type 2 diabetes. Eur J Clin Invest. 2014;44(8):736–42.